Differential approach in the treatment of chronic constipation in children with congenital bowel malformations

Authors: V.V. Berezhny, V.G. Kozachuk, V.F. Ribalchenko

National Medical Academy of Postgraduate Education named after P.L. Shupyk, Kyiv, Ukraine


Objective — to study the clinical efficacy of the drug «Medulak» in the complex therapy of chronic constipation in children that arose against the background of congenital malformation of the large intestine.

Patients and methods

A clinical study of 30 children with chronic constipation, which arose against the background of a congenital malformation of the large intestine, was carried out. The mean age of the patients was 7.5±2.1 years. The diagnosis was verified on the basis of anamnesis data, patient complaints, clinical examination, digital examination of the rectum, laboratory methods, ultrasound scanning of the abdominal organs, and irrigography. Patients in the complex of therapy received the drug “Medulac”. The effectiveness of therapy was monitored on the 15th and 30th day of treatment.

Results

According to the results of irrigography, signs of doliocolon were detected in 10 (33.3%) patients, megadolichocolon – in 6 (20%), megacolon – in 3 (10%), dolichocolon + Payr’s syndrome – in 3 (10%), megacolon + Payr’s syndrome — in 2 (6.6%), dolichocolon + megarectum — in 2 (6.6%), megadolichosigma — in one child. Before treatment, along with gastrointestinal disorders, dermatointerstitial and vegetative manifestations were observed in children. During the observation, the majority of children showed a violation of the intestinal microbiota. According to the results of a coprological study, 26 (86.7%) children had insufficient digestion of proteins, fats and carbohydrates. During treatment with Medulak, positive clinical dynamics were observed in all patients. On the 15th day of therapy, half of the patients did not have any clinical symptoms of constipation. A positive clinical effect was observed in the majority of children (93.3%).

Conclusions

The inclusion of the drug «Medulak»in the complex therapy of chronic constipation in children with congenital malformations of the large intestine has good therapeutic efficacy, improves the nature of the stool, stimulates intestinal motility, normalizes its microbiocenosis and prevents complications, which allows us to recommend its use in the practice of pediatricians, general practitioners practices – family doctors and pediatric surgeons.

Key words: children, constipation, congenital malformation of the large intestine, Medulak.

ARTICLES FROM CATEGORY
Support of educational events. Participation of World Medicine in the First Congress of Optometrists of Ukraine.
Cetirizine is an effective and safe antihistamine (literature review, results of clinical researches)
All-Ukrainian Scientific and Practical Conference “Aspects of Internal Medicine in Wartime 2024"

PROVE YOU ARE A MEDICAL PROFESSIONAL

Attention: This section is intended for healthcare professionals only. If you are not a medical professional, you can return to the main page by clicking the “No” option

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design